Immunome (IMNM) Total Non-Current Liabilities (2020 - 2023)

Immunome has reported Total Non-Current Liabilities for 4 years, with the latest figure at $27.3 million in Q4 2023.

• For the quarter ending Q4 2023, Total Non-Current Liabilities rose 272.64% year-over-year to $27.3 million; the trailing twelve-month figure through Dec 2023 stood at $27.3 million (up 272.64% YoY), and the FY2023 full-year result was $27.3 million, up 272.64% from the prior year.
• Total Non-Current Liabilities for Q4 2023 stood at $27.3 million, down from $87.0 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $87.0 million in Q3 2023, with the low at $5.6 million in Q3 2020.
• Historically, Total Non-Current Liabilities has averaged $20.3 million across 4 years, with a median of $9.2 million in 2022.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slipped 24.64% — and 2023, when it jumped 1080.12%.
• Immunome's Total Non-Current Liabilities stood at $5.6 million in 2020, then soared by 72.85% to $9.7 million in 2021, then declined by 24.64% to $7.3 million in 2022, then jumped by 272.64% to $27.3 million in 2023.
• The last three Total Non-Current Liabilities figures came in at $27.3 million (Q4 2023), $87.0 million (Q3 2023), and $7.3 million (Q4 2022), per Business Quant data.